Home > Healthcare > Analytical Instruments > Elemental Analysis > Label-free Array Systems Market

Label-free Array Systems Market - By Technology (Surface Plasmon Resonance, Bio-layer Interferometry, Microcantilever, Enthalpy Array, Atomic Force Microscopy), Application (Drug Discovery, Protein Interface Analysis), End-use – Global Forecast (2024 – 2032)

  • Report ID: GMI9649
  • Published Date: May 2024
  • Report Format: PDF

Label-free Array Systems Market Size

Label-free Array Systems Market size was valued at around USD 1.4 billion in 2023 and is estimated to grow at 7.2% CAGR from 2024 to 2032. Label-free array systems are advanced analytical platforms used for detecting and characterizing biomolecular interactions without the need for fluorescent, radioactive, or enzymatic labels. These systems measure changes in physical properties such as mass, refractive index, or electrical impedance to provide real-time data on binding events between biomolecules, such as proteins, nucleic acids, or small molecules.

Label-free Array Systems Market

The increasing drug discovery and development activities is a significant driver for the label-free array systems market. For instance, according to the National Institutes of Health, in 2023, these systems allow for high-throughput screening of potential drug candidates, enabling researchers to quickly and efficiently identify promising compounds. This capability is crucial in the early stages of drug discovery where large libraries of molecules are tested for biological activity. Furthermore, these systems provide real-time monitoring of biomolecular interactions without the need for labels that can alter the behavior of the molecules being studied.

Furthermore, increasing drug discovery services, advancement in drug discovery outsourcing services, advancements in biotechnology and life sciences research, surge in drug screening, government initiatives and funding, and increasing education & awareness, are the promoting factors advancing the growth of the market.

Label-free Array Systems Market Trends

The rising cases of chronic and infectious diseases is a significant driver for market. With increasing incidences of chronic and infectious diseases, there is a heightened demand for advanced diagnostic tools that can provide rapid, accurate, and real-time detection of biomarkers associated with these diseases.

  • According to the World Health Organization (WHO), in 2024, over 35 million new cancer cases are predicted in 2050, a 77% increase from the 20 million cases in 2022.
  • Similarly, as per the same report, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.
  • The surge in chronic and infectious diseases necessitates the development of new therapeutics. Label-free array systems are essential in the drug discovery process, as they enable detailed analysis of biomolecular interactions, helping researchers identify and develop effective drugs more efficiently.
  • Chronic diseases such as cancer, diabetes, and cardiovascular diseases, often require personalized treatment approaches. Label-free array systems facilitate the study of individual patient samples to identify specific biomarkers and tailor treatments, thereby increasing the growth of the market.

Label-free Array Systems Market Analysis

Label-free Array Systems Market, By Technology, 2021 – 2032 (USD Billion)

Based on technology, the market is classified into surface plasmon resonance, bio-layer interferometry, cellular dielectric spectroscopy, microcantilever, scanning kelvin nanoprobe, enthalpy array, atomic force microscopy, and other technologies. The surface plasmon resonance (SRP) segment is estimated to account for USD 669.2 million by the end of 2032.

  • SPR technology offers exceptional sensitivity and specificity in detecting and measuring biomolecular interactions. This makes it particularly useful for applications requiring precise quantification of binding affinities and kinetics, such as drug discovery, diagnostics, and biomolecular research.
  • It provides real-time monitoring of interactions without the need for labels. This real-time capability is crucial for understanding the dynamics of biomolecular interactions such as binding and dissociation rates, that are important in characterizing drug candidates and understanding biological processes.
  • Further, it is highly versatile and can be used to study a wide range of interactions, including protein-protein, protein-DNA, protein-small molecule, and cell-surface interactions. This versatility expands its applicability across various fields, including pharmaceuticals, biotechnology, and academic research.
  • SPR is a well-established and widely accepted technology in the scientific community. Its robust track record and extensive use in research and industry contribute to its dominant market position. Many researchers and institutions trust and rely on SPR for their experimental needs, thereby leading the segmental growth.
Label-free Array Systems Market, By Application (2023)

Based on application, the label-free array systems market is divided into drug discovery, protein interface analysis, antibody characterization and development, protein complex and cascade analysis, detection of disease biomarkers, and other applications. The drug discovery segment accounted for USD 483.6 million in 2023.

  • Drug discovery involves screening large libraries of compounds to identify potential drug candidates. Label-free array systems such as SPR and bio-layer interferometry (BLI), provide high-throughput screening capabilities, enabling researchers to quickly and efficiently identify promising compounds based on their binding affinities and kinetics.
  • The ability to conduct real-time analysis without the need for labeling reduces both the time and cost associated with drug screening. This efficiency is particularly valuable in the early stages of drug discovery, where large numbers of compounds must be tested rapidly and economically.
  • The quantitative data obtained from label-free array systems, such as kinetic rate constants and binding affinities are of high quality and crucial for making informed decisions in the drug development pipeline. These data help in understanding the potential efficacy and safety of drug candidates.
  • Further, modern label-free array systems are designed to integrate seamlessly with existing drug development workflows including automated sample handling and data analysis. This integration enhances productivity and allows for the efficient progression of drug candidates through the discovery pipeline.
  • Thus, such aforementioned factors are expected to enhance the segmental growth.

Based on end use, the label-free array systems market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, hospitals and clinics, and other end-users. The pharmaceutical & biotechnology companies segment held a market share of 38.3% in the year 2023.

  • These companies invest heavily in R&D to discover and develop new drugs and therapies. Label-free array systems are essential tools in this process, providing critical insights into biomolecular interactions, drug efficacy, and toxicity.
  • Pharmaceutical and biotechnology companies must generate reliable and reproducible data that meet regulatory standards. Label-free array systems provide high-quality data that can be used to support regulatory submissions and ensure compliance with industry standards.
  • Further, pharmaceutical and biotechnology companies are increasingly focusing on personalized medicine, developing treatments tailored to individual patients. Label-free array systems facilitate the study of patient-specific interactions, aiding in the development of personalized therapies.
  • Ongoing innovations in label-free technologies such as increased sensitivity, higher throughput, and improved data analysis capabilities, make these systems even more valuable to pharmaceutical and biotechnology companies. These advancements help drive their adoption and market share.
North America Label-free Array Systems Market, 2021 – 2032 (USD Million)

The U.S. label-free array systems market is anticipated to grow at CAGR of 6.9% during the analysis timeframe.

  • Increasing prevalence of chronic and infectious diseases is a significant factor for the growth of the market. For instance, according to the National Library of Medicine, in 2023, 1,958,310 new cases of cancer were diagnosed and 609,820 people died from the disease.
  • Further, as per American Diabetes, Association, in 2023, 37 million citizens were affected from diabetes including adults and youth. Thus leading to increased adoption of these systems and contributing to the substantial market share.

Germany label-free array systems market is anticipated to witness lucrative growth between 2024 – 2032.

  • The country is home to a robust biotechnology and pharmaceutical industry, with numerous companies engaged in drug discovery, development, and production. The presence of these industries drives the demand for advanced analytical technologies like label-free array systems.
  • German companies and research institutions are known for their willingness to invest in advanced technologies. This includes the adoption of state-of-the-art label-free array systems to enhance research capabilities and maintain a competitive edge in the global market.

Japan label-free array systems market is expected to grow significantly over the years.

  • Japan has a well-established biotechnology and pharmaceutical sector, with numerous companies engaged in cutting-edge research and development. This industry demands advanced analytical tools like label-free array systems to facilitate drug discovery, development, and production.
  • Additionally, the country is home to world-renowned universities and research institutions that conduct pioneering research in molecular biology, biochemistry, and related fields. These institutions rely on state-of-the-art label-free array systems to support their research activities.

UAE label-free array systems market is anticipated to witness lucrative growth between 2024 – 2032.

  • UAE government has made substantial investments in healthcare and biotechnology as part of its Vision 2021 and beyond. This strategic focus aims to diversify the economy and foster innovation, leading to increased demand for advanced technologies such as label-free array systems.
  • The country is rapidly developing its pharmaceutical and biotechnology sectors. With an increasing number of local and international companies setting up operations in the region, there is a heightened need for advanced analytical tools to support drug discovery and development efforts.

Label-free Array Systems Market Share

The label-free array systems industry is highly competitive, marked by several players striving for market dominance. Providers offer comprehensive products and techniques with improved efficiency and affordability. This includes advancements in processing, precision, automation, and customization. Competition is driven by factors such as the quality, reliability, and ease of usage along with integration capabilities with existing technologies, and compliance with regulatory standards. Strategic partnerships with companies and healthcare networks play a crucial role in market positioning.


Label-free Array Systems Market Companies

Some of the eminent market participants operating in the label-free array systems industry include:

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Corning Incorporated
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Merck KGaA
  • Meso Scale Diagnostics (MSD)
  • Nanion Technologies
  • Pall Corporation
  • PerkinElmer, Inc.
  • Sartorius AG
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

Label-free Array Systems Industry News:

  • In December 2023, Danaher Corporation completed the acquisition of Abcam plc, a supplier of protein research tools for life sciences based in Cambridge, England. This acquisition enriched the label-free array systems of the company. Thus, it increased the sales and revenues of the company.
  • In May 2022, Sartorius AG unveiled the new Octet SF3, the company's 1st surface plasmon resonance solution. Due to the system's low base-line noise and drift, large injection volumes, and novel injection techniques, users may generate better kinetics and the affinity data short time period. Thus, it increased the product portfolio of the company.

The label-free array systems market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Technology

  • Surface plasmon resonance
  • Bio-layer interferometry
  • Cellular dielectric spectroscopy
  • Microcantilever
  • Scanning kelvin nanoprobe
  • Enthalpy array
  • Atomic force microscopy
  • Other technologies

Market, By Application

  • Drug discovery
  • Protein interface analysis
  • Antibody characterization and development
  • Protein complex and cascade analysis
  • Detection of disease biomarkers
  • Other applications

Market, By End-use

  • Pharmaceutical & biotechnology companies
  • Academic & research institutes
  • Contract research organizations
  • Hospitals and clinics
  • Other end-users

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Netherlands
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of Middle East and Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global label-free array systems industry size was valued at USD 1.4 billion in 2023 and is estimated to grow at 7.2% CAGR from 2024 to 2032 due to increasing drug discovery and development activities and rising cases of chronic and infectious diseases.

The surface plasmon resonance (SRP) segment in the market is estimated to account for USD 669.2 million by 2032 because SRP technology offers sensitive and label-free detection of biomolecular interactions.

The drug discovery segment of the label-free array systems market accounted for USD 483.6 million in 2023 due to screening large libraries of compounds to identify potential drug candidates and the ability to conduct real-time analysis.

Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Corning Incorporated, Danaher Corporation, F. Hoffmann-La Roche AG, Illumina, Inc., Merck KGaA, Meso Scale Diagnostics (MSD), Nanion Technologies, and Pall Corporation, among others.

Label-free Array Systems Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 237
  • Countries covered: 23
  • Pages: 150
 Download Free Sample